Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple...
Danish biotech company Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation (MJFF) to assess sortilin inhibition in Parkinson’s disease.
A Series A financing round, led by Deerfield Management, is aimed at accelerating a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease.
US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.
Netherlands-based gene therapy company, VectorY Therapeutics, and Wageningen University have signed a strategic collaboration agreement for the development of novel baculovirus-based AAV production technologies.
Reaching the central nervous system is a difficult task, and getting a high enough dose to it poses an issue as well, but innovations are well underway to bridge a path across the blood-brain barrier.